Biologic therapy stands as an effective treatment for IBD; however, due to potential cost and safety concerns, de-escalation strategies, primarily for anti-TNF agents, have been proposed, especially following previous dose intensification. The gene discussed is TNF; the disease is inflammatory bowel disease.